Document:

Oracle Corporation Amended and Restated 1993 Directors' Stock Plan

 Exhibit 10.03 
 ORACLE CORPORATION 
 AMENDED AND RESTATED 1993 DIRECTORS’ STOCK PLAN

 (as amended and adjusted for stock splits through November 7, 2012) 

1. Establishment and Purpose. 
  

	 	(a)	Establishment. There is hereby adopted the Amended and Restated 1993 Directors’ Stock Plan (the “Plan”) of Oracle Corporation, a Delaware
corporation (the “Company”), which amends and restates the 1993 Directors’ Stock Option Plan which was originally adopted May 24, 1993, and was amended and restated on October 13, 2003; October 9,
2006; July 14, 2008; July 13, 2009 and November 7, 2012. The Plan is intended to provide a means whereby eligible members of the Board of Directors of the Company may be given an opportunity to acquire shares of Common Stock
of the Company. 

  

	 	(b)	Purpose. The purpose of the Plan is to enable the Company to attract and retain the best available individuals for service as members of the Board of Directors
of the Company, to provide additional incentive to such individuals while serving as directors, and to encourage their continued service on the Board of Directors. 

 2. Definitions. 
 As used herein, the following definitions shall apply:

  

	 	(a)	“Award” shall mean any Option or other stock-based award granted hereunder. 

 

	 	(b)	“Board” shall mean the Board of Directors of the Company. 

 

	 	(c)	“Code” shall mean the Internal Revenue Code of 1986, as amended. 

 

	 	(d)	“Committee” shall mean the Committee or Committees referred to in Section 4 of the Plan. If at any time no Committee shall be in office or
appointed by the Board to administer the Plan, then the functions of the Committee specified in the Plan shall be exercised by the Board. 

  

	 	(e)	“Common Stock” shall mean the Common Stock, $.01 par value per share, of the Company. 

 

	 	(f)	“Company” shall mean Oracle Corporation, a Delaware corporation. 

 

	 	(g)	“Continuous Status as a Director” shall mean the absence of any interruption or termination of service as a Director. 

 

	 	(h)	“Director” shall mean a member of the Board. 

  
 1 

	 	(i)	“Employee” shall mean any person, including any officer or Director, who is an employee of the Company, or any Subsidiary of the Company, for purposes
of tax withholding under the Code. The payment of a director’s fee by the Company shall not be sufficient in and of itself to constitute “employment” by the Company. 

 

	 	(j)	“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

 

	 	(k)	“Fair Market Value” shall mean, as of any date, the value of Common Stock determined as follows, unless otherwise determined by the Committee:

	 	(i)	the last reported sale price of the Common Stock of the Company on NASDAQ or, if no such reported sale takes place on any such day, the average of the closing bid and
asked prices, or 

	 	(ii)	if such Common Stock shall then be listed on another national securities exchange, the last reported sale price or, if no such reported sale takes place on any such
day, the average of the closing bid and asked prices on the principal national securities exchange on which the Common Stock is listed or admitted to trading, or 

	 	(iii)	if such Common Stock shall not be quoted on NASDAQ nor listed or admitted to trading on another national securities exchange, then the average of the closing bid and
asked prices, as reported by The Wall Street Journal for the over-the-counter market, or 

	 	(iv)	if none of the foregoing is applicable, then the Fair Market Value of a share of Common Stock shall be determined in good faith by the Committee in its discretion.

  

	 	(l)	“Option” shall mean an option to purchase shares of Common Stock granted pursuant to the Plan. All Options granted hereunder are not intended to
qualify as incentive stock options under Section 422 of the Code. 

  

	 	(m)	“Optioned Stock” shall mean the Common Stock subject to an Option. 

 

	 	(n)	“Optionee” shall mean an Outside Director who receives an Option. 

 

	 	(o)	“Outside Director” shall mean a Director who is not an Employee. 

 

	 	(p)	“Participant” shall mean an Outside Director who receives an Award hereunder. 

 

	 	(q)	“Securities Act” shall mean the Securities Act of 1933, as amended. 

 

	 	(r)	“Share” shall mean a share of the Common Stock, as adjusted in accordance with Section 12 of the Plan. 

 

	 	(s)	“Subsidiary” shall mean a “subsidiary corporation”, whether now or hereafter existing, as defined in Section 424(f) of the Code.

 3. Shares Subject to the Plan. Subject to the provisions of Section 12 of the Plan, the maximum number of Shares
which may be issued under the Plan after July 14, 2003 (including pursuant to the 

  
 2 

 
exercise of Options outstanding as of such date) is 2,587,830 shares of Common Stock, of which not more than an aggregate of 1,800,000 Shares shall be available for Awards granted pursuant to
Section 5(d) of the Plan. If an Award granted hereunder expires, terminates, becomes unexercisable or is forfeited for any reason, the underlying Shares shall become available for future grant under the Plan. 

4. Administration of the Plan. 
  

	 	(a)	Administrator. The Plan shall be administered by the Board or by the Committee appointed by the Board, which shall consist of two or more members of the Board.

  

	 	(b)	Powers of the Committee. Subject to the provisions and restrictions of the Plan, the Committee shall have the authority, in its discretion, to:
(i) determine the Fair Market Value of the Common Stock; (ii) determine the exercise price per Share; (iii) interpret the Plan; (iv) subject to Section 13, amend the Plan or any Award; (v) authorize any person to
execute on behalf of the Company any agreements or other documents in connection with the grant of an Award under the Plan; (vi) approve forms of agreement for use under the Plan; and (vii) make all other determinations deemed necessary or
advisable for the administration of the Plan. 

  

	 	(c)	Effects of Committee’s Decision. All decisions, determinations and interpretations of the Committee shall be final and binding on all holders of any Awards
granted under the Plan. 

 5. Option grants. 

 

	 	(a)	Automatic Grants. All grants of Options hereunder shall be automatic and nondiscretionary and shall be made in accordance with the provisions of this
Section 5, as may be amended by the Board or the Committee from time to time. 

  

	 	(b)	Initial Grants. As of the date on which any individual becomes an Outside Director, such individual shall be granted automatically an Option to purchase 60,000
shares. 

  

	 	(c)	Subsequent Grants. On May 31 of each year: 

  

	 	(i)	each Outside Director shall be granted automatically an option to purchase 45,000 shares, provided that on such date the Outside Director has served on the Board for at
least six months. 

	 	(ii)	 the Chairperson of the Finance and Audit Committee shall be granted automatically an Option to purchase 45,000 shares, provided that on such grant date
the Outside Director has served on the Finance and Audit Committee for at least one year. If such Outside Director has served on the Finance and Audit Committee for less than one year from such grant date, such Outside Director shall be granted
automatically an Option to purchase a pro rata amount of 45,000 shares based on the number of complete calendar months that such Outside Director served on the Finance and 

  
 3 

	 	
Audit Committee during the one year prior to such grant date. This grant shall be in addition to the options granted under any other provision of Section 5(c) hereof.

	 	(iii)	the Chairperson of the Compensation Committee shall be granted automatically an Option to purchase 45,000 shares, provided that on such date the Outside Director has
served on the Compensation Committee for at least one year. If such Outside Director has served on the Compensation Committee for less than one year from such grant date, such Outside Director shall be granted automatically an Option to purchase a
pro rata amount of 45,000 shares based on the number of complete calendar months that such Outside Director served on the Compensation Committee during the one year prior to such grant date. This grant shall be in addition to the options granted
under any other provision of Section 5(c) hereof. 

	 	(iv)	the Chairperson of the Nomination and Governance Committee shall be granted automatically an Option to purchase 15,000 shares, provided that on such date the Outside
Director has served on the Nomination and Governance Committee for at least one year. If such Outside Director has served on the Nomination and Governance Committee for less than one year from such grant date, such Outside Director shall be granted
automatically an Option to purchase a pro rata amount of 15,000 shares based on the number of complete calendar months that such Outside Director served on the Nomination and Governance Committee during the one year prior to such grant date. This
grant shall be in addition to the options granted under any other provision of Section 5(c) hereof. 

	 	(v)	the Vice Chairperson of the Finance and Audit Committee shall be granted automatically an Option to purchase 30,000 shares, provided that on such date the Outside
Director has served on the Finance and Audit Committee for at least six months. If such Outside Director has served on the Finance and Audit Committee for less than six months from such grant date, such Outside Director shall be granted
automatically an Option to purchase a pro rata amount of 30,000 shares based on the number of complete calendar months that such Outside Director served on the Finance and Audit Committee during the six months prior to such grant date. This grant
shall be in addition to the options granted under any other provision of Section 5(c) hereof. 

	 	(vi)	the Chairperson of the Committee on Independence Issues shall be granted automatically an Option to purchase 15,000 shares, provided that on such date the Outside
Director has served on the Committee on Independence Issues for at least six months. If such Outside Director has served on the Committee on Independence Issues for less than six months from such grant date, such Outside Director shall be granted
automatically an Option to purchase a pro rata amount of 15,000 shares based on the number of complete calendar months that such Outside Director served on the Committee on Independence Issues during the six months prior to such grant date. This
grant shall be in addition to the options granted under any other provision of Section 5(c) hereof. 

  

	 	(d)	 Other Stock Awards. The Board shall have the discretion to grant awards of restricted stock, restricted stock units, deferred shares or other
stock-based awards in lieu of the automatic Option grants (in whole or in part) pursuant to paragraphs (b) and (c) above. The number of Shares subject to any such stock award granted pursuant to the foregoing

  
 4 

	 	
sentence shall have an equivalent value, as determined on any reasonable basis by the Board, to the number of Options that would have been granted. Any such stock award shall be subject to
similar terms as would apply to options granted under paragraphs (b) and (c) with respect to vesting or forfeiture schedules, treatment on termination of status as director, and transfer restrictions. Subject to the foregoing limitations
and the provisions of the Plan, the terms and conditions of any such stock awards shall be set forth in the applicable award agreement as determined by the Board. 

 

	 	(e)	Limitations. 

  

	 	(i)	Notwithstanding the provisions of Sections 5(b) and 5(c) hereof, in the event that a sufficient number of Shares is not available under the Plan for the grant of
Awards, the remaining Shares shall be prorated based upon the number of Shares each Director was entitled to receive under this Plan. Any further grants shall then be deferred until such time, if any, as additional Shares become available for grant
under the Plan. Subject to the terms of Section 13 hereof, the Board shall have the authority at any time to make additional Shares available for grant under the Plan, subject to obtaining stockholder approval of such increase to the extent
required under Section 13(a) hereof. 

	 	(ii)	Notwithstanding the provisions of Section 5(b) and 5(c) hereof, any grant made before the Company has obtained stockholder approval of the Plan, and any grant made
after amendment of the Plan where such amendment of the Plan requires stockholder approval under Section 13(a) hereof, shall be conditioned upon obtaining such stockholder approval. 

6. Terms and Conditions of Options. 
  

	 	(a)	Stock Option Agreement. Each Option granted pursuant to this Plan shall be evidenced by a stock option agreement (“Option Agreement”) containing such
terms and conditions that are consistent with this Plan and as otherwise determined by the Committee. 

  

	 	(b)	Exercise Price. The exercise price per share shall be 100% of the Fair Market Value per Share on the date of grant of the Option, subject to adjustment to the
extent provided in Section 12 hereof. 

  

	 	(c)	Vesting. Unless otherwise determined by the Committee, the Shares shall vest and become exercisable at the rate of twenty-five percent (25%) of the Optioned
Stock on each anniversary of the date of grant. 

  

	 	(d)	Term. The term of each Option shall be ten (10) years from the date of grant, unless (i) a shorter period is required to comply with any applicable
law, in which case such shorter period will apply or (ii) the Committee determines that a term of less than ten years shall apply. 

  
 5 

 7. Eligibility. Awards hereunder may be granted only to Outside Directors. The Plan shall not confer
upon any Outside Director any right with respect to continuation of service as a Director or nomination to serve as a Director, nor shall it interfere in any way with any rights which the Director or the Company may have to terminate his or her
directorship at any time. 
 8. Payment Upon Exercise. Payment of the exercise price of any Award shall be made (i) by cash or
check; (ii) to the extent not prohibited by the Board or by applicable law, and provided that a public market for the Company’s stock exists, through a “same day sale” commitment from the Participant and a broker-dealer that is a
member of the National Association of Securities Dealers (an “NASD Dealer”) whereby Participant irrevocably elects to exercise the Award and to sell a portion of the Shares so purchased to pay for the exercise price and whereby the NASD
Dealer irrevocably commits upon receipt of such Shares to forward the exercise price directly to the Company; or (iii) as otherwise determined by the Board and as permitted by applicable law or regulation. 

9. Withholding Taxes. Whenever, under the Plan, Shares are to be issued pursuant to any Award granted hereunder, the Company shall have the right
to require the recipient to remit to the Company an amount of cash sufficient to satisfy any applicable federal, state or local income and employment tax withholding requirements prior to the delivery of any certificate or certificates for such
Shares. 
  

	10.	Exercise of Options. 

  

	 	(a)	Procedure for Exercise. An Option shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the terms
of the Option Agreement by the person entitled to exercise the Option and full payment for the Shares has been received by the Company in accordance with Section 8 hereof. An Option may not be exercised for a fraction of a Share.

  

	 	(b)	Rights as a Stockholder. Notwithstanding the exercise of the Option, until the issuance (as evidenced by the appropriate entry on the books of a duly authorized
transfer agent of the Company) of the stock certificate evidencing such Shares, no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock. A stock certificate for the number of Shares
so acquired shall be issued to the Optionee as soon as practicable after exercise of the Option. No adjustment will be made for a dividend or other right if the record date is prior to the date the stock certificate is issued.

  

	 	(c)	 Termination of Status as Director. Except as set forth in Section 10(d) or (e), if an Outside Director ceases to serve as a Director, he or
she may, but only within three (3) months (or such other period of time not exceeding six (6) months as is determined by the Board) after the date he or she ceases to be a Director of the Company, exercise his or her Option to the extent
that he or she was entitled to exercise it at the date of such termination. Notwithstanding the foregoing, in no event may the Option be exercised after its term set forth in Section 6 has expired. To the extent that such Outside Director was
not entitled to exercise an Option at the date of termination, or if such Outside 

  
 6 

	 	
Director does not exercise such Option (which he or she was entitled to exercise) within the time specified, the Option shall terminate. 

 

	 	(d)	Disability of Director. Notwithstanding the provisions of Section 10(c) above, in the event an Outside Director is unable to continue his or her service as
a Director with the Company as a result of his or her total and permanent disability (as defined in Section 22(e)(3) of the Code), he or she may, within six months from the date of such termination, exercise his or her Option to the extent he
or she was entitled to exercise it at the date of such termination. Notwithstanding the foregoing, in no event may the Option be exercised after the expiration of the term set forth in Section 6. To the extent that Optionee was not entitled to
exercise the Option at the date of termination, or if Optionee does not exercise such Option (which he or she was entitled to exercise) within the time specified herein, the Option shall terminate. 

 

	 	(e)	Death of Optionee. In the event of the death of an Outside Director: 

 

	 	(i)	If the Outside Director dies during the term of the Option, is a Director at the time of his or her death and has been in Continuous Status as a Director since the date
of grant of the Option, the Option may be exercised at any time within six (6) months following the date of death by the Outside Director’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but
only to the extent the Outside Director was entitled to exercise the Option at the date of termination. Notwithstanding the foregoing, in no event may the Option be exercised after the expiration of the term set forth in Section 6.

	 	(ii)	If the Outside Director dies within three (3) months after the termination of Continuous Status as a Director, the Option may be exercised at any time within six
(6) months following the date of death by the Optionee’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent the Outside Director was entitled to exercise the Option at the
date of termination. Notwithstanding the foregoing, in no event may the Option be exercised after the expiration of the term set forth in Section 6. 

 11. Nontransferability of Awards. Awards granted under this Plan, and any interest therein, shall not be transferable or assignable by the Participant, and may not be made subject to execution,
attachment or similar process, otherwise than by will or by the laws of descent and distribution, and shall be exercisable during the lifetime of the Participant only by the Participant; provided, however; that Awards held by a Participant may be
transferred to such family members, trusts and charitable institutions as the Committee, in its sole discretion, shall approve, unless otherwise restricted from such transfer under the terms of the Award. The designation of a beneficiary by a
Participant does not constitute a transfer. 
 12. Adjustment Upon Changes in Capitalization. 

 

	 	(a)	 Adjustment of Shares. In the event that the number of outstanding shares of Common Stock of the Company is changed by a stock dividend, stock
split, reverse stock split, combination, reclassification or similar change in the capital structure of the Company 

  
 7 

	 	
without consideration, the number of Shares available under this Plan, the number of Shares deliverable in connection with any Award and, if applicable, the exercise price per Share thereof shall
be proportionately adjusted, subject to any required action by the Board or stockholders of the Company and compliance with applicable securities laws; provided however, that no certificate or scrip representing fractional shares shall be issued and
any resulting fractions of a share shall be ignored. 

  

	 	(b)	Change of Control. In the event of a dissolution or liquidation of the Company, a merger in which the Company is not the surviving corporation (other than a
merger with a wholly owned subsidiary or where there is no substantial change in the stockholders of the Company and the obligations of the Company under this Plan are assumed by the successor corporation), the sale of substantially all of the
assets of the Company, or any other transaction described under Section 424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition of all or substantially all of
the outstanding shares of the Company), all outstanding Awards, notwithstanding any contrary terms of the Plan, shall accelerate and become vested and exercisable in full prior to and shall expire on the consummation of such dissolution,
liquidation, merger or sale of assets. 

  

	 	(c)	Acceleration Upon Unfriendly Takeover. Notwithstanding anything in Section 12(b) hereof to the contrary, if fifty percent (50%) or more of the
outstanding voting securities of the Company become beneficially owned (as defined in Rule 13d-3 promulgated by the Securities and Exchange Commission) by a person (as defined in Section 2(2) of the Securities Act and in Section 13(d)(3)
of the Exchange Act) in a transaction or series of transactions expressly disapproved by the Board, then all outstanding Awards under this Plan shall become immediately vested and exercisable with no further act or action required by the Committee.

 13. Amendment and Termination of the Plan. 

 

	 	(a)	Amendment. The Board or the Committee may amend the Plan from time to time in such respects as the Board or the Committee, as the case may be, may deem
advisable; provided that, to the extent necessary to comply with any applicable law or regulation, the Company shall obtain approval of the Company’s stockholders to amend the Plan to the extent and in the manner required by such law or
regulation. 

  

	 	(b)	Termination or Suspension. Unless sooner terminated pursuant to this Section 13, the Plan shall terminate on the date that all shares of Common Stock
reserved for issuance under the Plan have been issued. The Committee, without further approval of the stockholders, may at any time terminate or suspend the Plan. Except as otherwise provided herein, any such termination or suspension of the Plan
shall not affect Awards already granted hereunder and such Awards shall remain in full force and effect as if the Plan had not been terminated or suspended. 

 

	 	(c)	 Outstanding Awards. Except as otherwise provided herein, rights and obligations under any outstanding Award shall not be altered or impaired by
amendment, suspension 

  
 8 

	 	
or termination of the Plan, except with the consent of the person to whom the Award was granted. The Committee shall have the authority to modify, extend or renew outstanding Awards and to
authorize the grant of new Awards in substitution therefor; provided that the Committee shall not, without the approval of the Company’s stockholders, directly or indirectly reduce the exercise price of any outstanding Award.

 14. Conditions Upon Issuance of Shares. Shares shall not be issued pursuant to any Award hereunder unless the issuance
and delivery of such Shares shall comply with all relevant provisions of law, including, without limitation, the Securities Act, the Exchange Act, the rules and regulations promulgated thereunder, state securities laws, and the requirements of any
stock exchange upon which the Shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance. 
 As a condition to the issuance of Shares pursuant to any Award, the Company may require the Participant to represent and warrant that the Shares are being acquired only for investment and without any
present intention to sell or distribute such Shares, if, in the opinion of counsel for the Company, such a representation is required by any of the relevant provisions of the law. 
 Inability of the Company to obtain authority from any regulatory body having jurisdictional authority deemed by the Company’s counsel to be necessary for the lawful issuance and sale of any Shares
hereunder shall relieve the Company of any liability for failure to issue or sell such Shares. 
 15. Reservation of Shares. The Company,
during the term of this Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan. 
 16. Rule 16b-3. The grant of Awards hereunder to persons subject to Section 16 of the Exchange Act shall comply with the applicable provisions of Rule 16b-3. The Company intends this Plan to
be a “formula plan” under Rule 16b-3 with respect to Awards granted hereunder. 

  
 9Tax Matters Agreement

 Exhibit 10.1 
 EXECUTION COPY 
  

 
  

TAX MATTERS AGREEMENT 
 by and between 
 ELAN CORPORATION, PLC 

AND 
 PROTHENA
CORPORATION PLC, 
 Dated 20 December 2012 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE I
	  			
		
	 DEFINITIONS
	  			
			
	 Section 1.01
	  	Definition of Terms	  	 	2	  
		
	 ARTICLE II
	  			
		
	 ALLOCATION OF TAXES
	  			
			
	 Section 2.01
	  	Ordinary Course Taxes	  	 	7	  
	 Section 2.02
	  	Transaction Taxes	  	 	7	  
	 Section 2.03
	  	Transfer Taxes	  	 	8	  
	 Section 2.04
	  	Entitlement to Tax Attributes	  	 	9	  
	 Section 2.05
	  	Additional Costs	  	 	9	  
		
	 ARTICLE III
	  			
		
	 TAX RETURN FILING AND PAYMENT OBLIGATIONS
	  			
			
	 Section 3.01
	  	Tax Return Preparation and Filing	  	 	9	  
	 Section 3.02
	  	Treatment of Transactions and Reporting Obligations	  	 	10	  
	 Section 3.03
	  	VAT	  	 	10	  
		
	 ARTICLE IV
	  			
		
	 TAX-FREE TREATMENT OF DISTRIBUTION & RELATED TRANSACTIONS
	  			
			
	 Section 4.01
	  	Representations	  	 	10	  
	 Section 4.02
	  	Covenants	  	 	11	  
		
	 ARTICLE V
	  			
		
	 TAX CONTESTS; INDEMNIFICATION; COOPERATION
	  			
			
	 Section 5.01
	  	Notice	  	 	13	  
	 Section 5.02
	  	Control of Tax Contests	  	 	13	  
	 Section 5.03
	  	Indemnification Payments	  	 	13	  
	 Section 5.04
	  	Interest on Late Payments	  	 	14	  
	 Section 5.05
	  	Treatment of Indemnity Payments	  	 	14	  
	 Section 5.06
	  	Cooperation	  	 	14	  
	 Section 5.07
	  	Confidentiality	  	 	15	  

  
 -i-

							
		
	 ARTICLE VI
	  			
		
	 DISPUTE RESOLUTION
	  			
			
	 Section 6.01
	  	Tax Disputes	  	 	15	  
		
	 ARTICLE VII
	  			
		
	 MISCELLANEOUS
	  			
			
	 Section 7.01
	  	Authorization	  	 	16	  
	 Section 7.02
	  	Expenses	  	 	16	  
	 Section 7.03
	  	Entire Agreement	  	 	16	  
	 Section 7.04
	  	Governing Law	  	 	16	  
	 Section 7.05
	  	Notice	  	 	16	  
	 Section 7.06
	  	Priority of Agreements	  	 	18	  
	 Section 7.07
	  	Amendments and Waivers	  	 	18	  
	 Section 7.08
	  	Termination	  	 	18	  
	 Section 7.09
	  	No Third Party Beneficiaries	  	 	19	  
	 Section 7.10
	  	Assignability	  	 	19	  
	 Section 7.11
	  	Enforcement	  	 	19	  
	 Section 7.12
	  	Survival	  	 	19	  
	 Section 7.13
	  	Construction	  	 	19	  
	 Section 7.14
	  	Severability	  	 	20	  
	 Section 7.15
	  	Counterparts	  	 	20	  
	 Section 7.16
	  	Successors	  	 	20	  

  
 -ii-

 TAX MATTERS AGREEMENT 

THIS TAX MATTERS AGREEMENT (this “Agreement”) is made and entered into as of 20 December 2012 by and between Elan
Corporation, plc, an Irish public limited company (“Parent”), and Prothena Corporation plc, an Irish public limited company (“Prothena”) (and Parent and Prothena, collectively, the “Companies”).

 WHEREAS, the board of directors of Parent has determined that it would be appropriate and desirable to separate a substantial
portion of the drug discovery business platform from Parent; 
 WHEREAS, the board of directors of Parent has approved and
declared advisable the separation of a substantial portion of Parent’s drug discovery business platform pursuant to a “demerger” under Irish law in which Parent will contribute such drug discovery business platform to Prothena (such
transfer, the “Prothena Transfer”) in exchange for Prothena issuing directly to holders of ordinary shares of Parent and American Depositary Shares (“ADSs”) of Parent, on a pro rata basis, Prothena ordinary shares
representing 100% of Prothena’s outstanding ordinary shares (such direct share issuance, the “Distribution”); 
 WHEREAS, Parent and Prothena have entered into the Demerger Agreement pursuant to which Parent shall effect the Prothena Transfer and the Distribution; 

WHEREAS, immediately following the Distribution, Elan Science One Limited, a wholly-owned subsidiary of Parent, will subscribe for 18% of
Prothena’s outstanding ordinary shares in exchange for cash; 
 WHEREAS, the Companies intend that the Prothena Transfer
and the Distribution (taken together) should not give rise to a chargeable gain for Parent in respect of the disposal by Parent of Neotope Biosciences, pursuant to Section 615 of the Taxes Consolidation Act, 1997 of Ireland (the
“TCA”) and should be relieved from Irish stamp duty for which Prothena would otherwise be accountable for, pursuant to Section 80 of the Stamp Duties Consolidation Act, 1999 of Ireland (the “SDCA”); 

WHEREAS, the Companies intend (and save in respect of any cash received in lieu of Prothena ordinary shares) that the Prothena Transfer
and the Distribution (taken together) shall qualify as a “scheme of reconstruction or amalgamation” pursuant to section 587 of the TCA with the result that no chargeable gain for Irish Tax purposes shall arise for shareholders in Parent
within the charge to Irish Tax as a result of the receipt of shares in connection with the Distribution; 

 WHEREAS, the Companies intend that the (i) Prothena Transfer, taken together with the
Distribution, qualify as a “reorganization” under Code Section 368(a)(1)(D), and (ii) the Distribution, as such, qualify as a distribution of Prothena ordinary shares to Parent shareholders pursuant to Code Section 355; and

 WHEREAS, the Companies desire to allocate the Tax responsibilities, liabilities and benefits of certain transactions and to
provide for certain other Tax matters. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained
herein, the Companies (each on behalf of itself and each of its subsidiaries as of the Closing Date and its future subsidiaries) hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 

Section 1.01 Definition of Terms. 
 The following terms shall have the following meanings (such meanings to apply equally to both the singular and the plural forms of the terms defined). Unless otherwise stated, all Section references are
to this Agreement. Any capitalized terms used herein and not otherwise defined shall have the meaning given to such term in the Demerger Agreement. 
 “Active Trade or Business” means the active conduct (determined in accordance with Code Section 355(b)) of the business conducted, prior to the Distribution, by Parent and its
subsidiaries and, after the Distribution, by the Prothena Group members independently and with separate employees. For these purposes, members shall include only those members that are part of the “separate affiliated group” of Parent or
Prothena, as applicable, within the meaning of Code Section 355(b)(3)(B). 
 “Additional Costs” means
liabilities, damages, penalties, judgments, assessments, losses, costs and expenses (including reasonable attorneys’ and accountants’ fees and expenses), whether arising under strict liability or otherwise, in each case, arising out of or
incident to the imposition, assessment or assertion of any Tax or adjustment against a party with respect to an amount for which such party is entitled to indemnification under this Agreement. 

“Adjustment Request” means any formal or informal claim or request for a Refund filed with any Taxing Authority.

 “ADSs” has the meaning set forth in the recitals. 

“Agreement” has the meaning set forth in the recitals. 

“Closing Date” means the date on which the Distribution is consummated. 

“Code” means the U.S. Internal Revenue Code of 1986, as amended. 

  
 -2-

 “Companies” has the meaning set forth in the recitals. 

“Demerger Agreement” means the Demerger Agreement, dated as of November 8, 2012, between Parent and Prothena, as
may be amended from time to time. 
 “Distribution” has the meaning set forth in the recitals. 

“Equity Investment” means Prothena’s potential cash issuance of common shares, ordinary shares, American Depository
Receipts, ADSs and/or preferred shares to investors after the Transactions. 
 “Final Determination” means the
final resolution of any Tax liability for any Tax period by or as a result of (i) a final and unappealable decision, judgment, decree or other order by any court of competent jurisdiction, (ii) a final settlement with the United States
Internal Revenue Service, a closing agreement or accepted offer in compromise under Code Sections 7121 or 7122, or a comparable arrangement under the laws of Ireland or another jurisdiction, (iii) any allowance of a Refund in respect of an
overpayment of Tax, but only after the expiration of all periods during which such amount may be recovered by the jurisdiction imposing such Tax, or (iv) any other final disposition, including by reason of the expiration of the applicable
statute of limitations. 
 “Indemnitee” has the meaning set forth in Section 5.01. 

“Indemnifying Party” has the meaning set forth in Section 5.01. 

“Irish Group Relief” means any loss, allowance or other amount eligible for surrender by way of group relief in
accordance with the TCA. 
 “Joint Return” means any Tax Return filed by a Tax Group that includes at least one
Parent Group member and at least one Prothena Group member. 
 “Neotope Biosciences” means Neotope Biosciences
Limited, an Irish private limited company and currently a wholly owned subsidiary of Parent; 
 “Onclave” mean
Onclave Therapeutics Limited, an Irish private limited company and currently a wholly owned subsidiary of Parent. 

“Parent” has the meaning set forth in the recitals. 

“Parent Capital Stock” means (ii) all classes or series of outstanding capital stock of Parent for U.S. federal
income Tax purposes, including ordinary shares, ADSs and all other instruments treated as outstanding equity in Parent for U.S. federal income Tax purposes, and (ii) all options, warrants and other rights to acquire such capital stock.

 “Parent Group” means Parent and each of its subsidiaries, in each case, including any successors thereof,
but excluding Prothena and each of its subsidiaries. 

  
 -3-

 “Parent Group Taxes” means any Tax imposed on or payable by the Parent
Group or any member thereof for any Tax period whether or not by reason of being a member of any Tax Group. 
 “Parent
Representation Letter” means the representation letter executed by Parent in connection with the delivery of the Tax Opinions. 
 “Post-Distribution Period” means the portion of the Closing Date after the completion of the Distribution and any date thereafter. 

“Pre-Closing Period” means any Tax period ending on or before the Closing Date and the portion of any Straddle
Period ending on the Closing Date. 
 “Proceedings” has the meaning set forth in Section 7.04. 

“Prothena” has the meaning set forth in the recitals. 

“Prothena Capital Stock” means (i) all classes or series of outstanding capital stock of Prothena for U.S. federal
income Tax purposes, including ordinary shares, preferred shares and all other instruments treated as outstanding equity in Prothena for U.S. federal income Tax purposes, and (ii) all options, warrants and other rights to acquire any such
capital stock (including ordinary shares). 
 “Prothena Group” means Prothena and each of its subsidiaries, in
each case, including any successors thereof, but excluding, for the avoidance of doubt, any member of the Parent Group. 

“Prothena Group Taxes” means (i) in the case of a Prothena Separate Return, any Tax imposed on or payable by the
Prothena Group or any member thereof, and (ii) in the case of a Joint Return, the aggregate Tax liability of the Prothena Group member(s), as determined by Parent pursuant to Section 3.01. 

“Prothena Representation Letter” means the representation letter executed by Prothena in connection with the delivery of
the Tax Opinions. 
 “Prothena Separate Return” means any Tax Return (other than a Joint Return) that includes
or relates to any Prothena Group member (including any such Tax Return filed by or on behalf of a Tax Group). 

“Prothena Transfer” has the meaning set forth in the recitals. 

“Refund” means any cash refund of Taxes or reduction of Taxes by means of credit, offset or otherwise, together with any
interest received or credited thereon. 
 “Restricted Period” means the period commencing upon the Closing Date
and ending at the close of business on the first day following the second anniversary of the Closing Date. 

  
 -4-

 “SDCA” has the meaning set forth in the recitals. 

“Straddle Period” means a Tax period beginning on or before and ending after the Closing Date. 

“Tax” or “Taxes” shall mean all forms of taxation, whenever created or imposed, and whether of the
United States, Ireland or elsewhere, and whether imposed by a federal, state, municipal, governmental, territorial, local, foreign or other body, and without limiting the generality of the foregoing, shall include net income, gross income, capital
gains, gross receipts, sales, use, value added, ad valorem, transfer, recording, franchise, profits, license, lease, service, service use, payroll, wage, withholding, employment, unemployment insurance, workers compensation, social security, excise,
severance, stamp, business license, business organization, occupation, premium, property, environmental, windfall profits, customs, duties, alternative minimum, estimated or other taxes, fees, premiums, assessments or charges of any kind whatever
imposed or collected by any governmental entity or political subdivision thereof, together with any related interest, charges, penalties, additions to such tax or additional amounts imposed with respect thereto by such governmental entity or
political subdivision. 
 “Tax Advisor” has the meaning set forth in Section 6.01. 

“Tax Attributes” means net operating losses, capital losses, investment credits, foreign Tax credits, excess charitable
contributions, general business credits, or any other loss, deduction, credit or other comparable item that could reduce a Tax liability. 
 “Tax Contest” means an audit, review, examination or any other administrative or judicial proceeding with the purpose or effect of redetermining Taxes (including any administrative or
judicial review of any Adjustment Request). 
 “Tax Dispute” means any dispute arising in connection with this
Agreement. 
 “Tax-Free Treatment” means (i) for U.S. federal, state or local Tax purposes,
(x) the Prothena Transfer and Distribution, taken together, qualifying as a transaction that is described in Code Sections 355(a) and 368(a)(1)(D), in which the Prothena ordinary shares distributed are “qualified property” under Code
Section 361(c) and Parent shareholders recognize no income or gain for U.S. federal income Tax purposes under Code Section 355 (except to the extent of any cash received in lieu of fractional Prothena ordinary shares), and (y) to the
extent applicable, the Transactions qualify for Tax-Free Treatment under comparable provisions of U.S. state and local Tax law; and (ii) for Irish Tax purposes, the Prothena Transfer and Distribution, taken together, qualifying as (x) a
transaction that falls within the provisions of both section 615 of the TCA and Section 80 of the SDCA and, as a result, does not give rise to a chargeable gain for Parent on the disposal of Neotope Biosciences and does not give rise to a
charge to stamp duty in respect of the transfer of the shares in Neotope Biosciences to Prothena and (y) save in respect of the receipt of any cash in lieu of fractional Prothena ordinary shares, a transaction that falls within Section 587
of the TCA and, as a result, the receipt of Prothena ordinary shares in connection with the Distribution does not give rise to a chargeable gain for shareholders of Parent within the charge to Irish Tax. 

  
 -5-

 “Tax Group” means two or more entities that file a Tax Return under
applicable Tax law on an affiliated, consolidated, combined, unitary or other group basis or that are otherwise treated as members of the same group for relevant Tax purposes. 
 “Tax Opinions” means the opinions obtained by Parent with respect to the Prothena Transfer and Distribution. 
 “Tax Return” means any return, filing, report, questionnaire, information statement, claim for Refund, or other document required or permitted to be filed, including any amendments
thereto, for any Tax period with any Taxing Authority. 
 “Taxing Authority” means any governmental authority
imposing Taxes. 
 “TCA” has the meaning set forth in the recitals. 

“Third Party Transaction Taxes” means all liabilities relating to Taxes of any third party, including any Parent
shareholder, for which any Parent Group or Prothena Group member, as the case may be, is or becomes liable, resulting from, or arising in connection with, the failure of the Prothena Transfer and Distribution to qualify for Tax-Free Treatment,
including any liability of Parent under applicable securities laws relating to the failure of the Transactions to qualify for Tax-Free Treatment. 
 “Transaction Document” means any document executed by Parent and/or Prothena, as the case may be, in connection with the Transactions, including this Agreement, the Demerger Agreement,
the Parent Representation Letter and the Prothena Representation Letter. 
 “Transaction Taxes” means all U.S.
federal, state and local income and franchise Taxes and any Irish Taxes of any Parent Group member or Prothena Group member, as the case may be, resulting from, or arising in connection with, the failure of any of the Prothena Transfer and the
Distribution to qualify for Tax-Free Treatment. 
 “Transactions” means the Prothena Transfer and Distribution,
as contemplated by the Demerger Agreement and other relevant documents. 
 “Transfer Taxes” means any stamp,
sales, use, gross receipts, value added, goods and services, harmonized sales, land transfer or other transfer Taxes imposed in connection with, or that are otherwise related to, the Transactions. For the avoidance of doubt, “Transfer
Taxes” shall not include any income or franchise Taxes payable in connection with the Transactions or Taxes in lieu of any such income or franchise Taxes. 
 “Unqualified Opinion” means an opinion obtained by Prothena (at its sole expense), in form and substance satisfactory to Parent, providing that the completion of a proposed action by the
Prothena Group (or, in each case, any member thereof) prohibited by Section 4.02(b) or (c) below would not affect the Tax-Free Treatment. Any Unqualified Opinion shall be delivered by nationally recognized U.S. tax counsel or Irish tax
counsel acceptable to Parent, as applicable, and Parent shall use its reasonable best efforts to determine whether such Unqualified Opinion is reasonably satisfactory to Parent within 30 Business Days of the receipt of such Unqualified Opinion by
Parent. 

  
 -6-

 “VAT” means value added Tax payable or recoverable pursuant to the VATCA.

 “VAT Group” has the meaning set forth in Section 3.03(a). 

“VATCA” means the Value-Added Tax Consolidation Act, 2010 of Ireland. 

ARTICLE II 

ALLOCATION OF TAXES 
 Section 2.01 Ordinary Course Taxes. 
 (a) Except as provided in
Sections 2.02 and 2.03 below, Parent shall indemnify each Prothena Group member against, and hold it harmless from, all Parent Group Taxes. 
 (b) Except as provided in Sections 2.02 and 2.03 below, each Prothena Group member, jointly and severally, shall indemnify each Parent Group member against, and hold it harmless from, all Prothena Group
Taxes (including Taxes payable upon the completion of a Tax Contest, as provided in Section 5.02). 
 (c) If, with respect
to any Prothena Group Tax, the Parent Group (or any member thereof) subsequently receives (or realizes) a Refund, it shall remit to Prothena, within 30 days, the amount of such Refund net of any Taxes or other expenses incurred by the Parent Group
(or any member thereof) in connection with the Refund. 
 (d) Except as provided in Section 2.01(e) below, if, with respect
to any Parent Group Tax, the Prothena Group (or any member thereof) subsequently receives (or realizes) a Refund, it shall remit to Parent, within 30 days, the amount of such Refund net of any Taxes or other expenses incurred by the Prothena Group
(or any member thereof) in connection with the Refund. 
 (e) The Prothena Group, except to the extent not permitted by law,
shall elect to forego, and/or shall not claim, carrybacks of any Tax Attributes of the Prothena Group to a Pre-Closing Period. For the avoidance of doubt, the Prothena Group shall have no claim against the Parent Group (whether pursuant to the terms
of this Agreement or otherwise) to the extent that any Tax Attributes of the Prothena Group available to the Prothena Group as of the Closing Date are subsequently determined to be invalid or are otherwise not available to any Prothena Group member.

 Section 2.02 Transaction Taxes. 
 (a) Subject to the relative fault provision in Section 2.02(c) below, each Prothena Group member, jointly and severally, shall indemnify each Parent Group member against, and hold it harmless from,
any Transaction Taxes and Third Party Transaction Taxes attributable to: 
 (i) any inaccurate representation of
fact, plan or intent made by Prothena in Section 4.01 of this Agreement or in the Prothena Representation Letter; and 

  
 -7-

 (ii) any action or omission by Prothena or any of its Affiliates in the
Post-Distribution Period, other than any action or omission (x) contemplated under any Transaction Document, or (y) that was taken or omitted in reliance upon any representation, warranty or covenant made by Parent in this Agreement or the
Parent Representation Letter to the extent such representation or warranty is incorrect or such covenant was breached, in whole or in relevant part. 
 (b) Subject to the relative fault provision in Section 2.02(c) below, Parent shall indemnify each Prothena Group member against, and hold it harmless from, any Transaction Taxes and Third Party
Transaction Taxes attributable to: 
 (i) any inaccurate representation of fact, plan or intent made by Parent in
Section 4.01 of this Agreement or in the Parent Representation Letter; and 
 (ii) any action or omission by
Parent or any of its Affiliates in the Post-Distribution Period, other than any action or omission (x) contemplated under any Transaction Document, or (y) that was taken or omitted in reliance upon any representation, warranty or covenant
made by Prothena in this Agreement or the Prothena Representation Letter to the extent such representation or warranty is incorrect or such covenant was breached, in whole or in relevant part. 

(c) If the liability for any Transaction Taxes or Third Party Transaction Taxes arises as a result of or is attributable to (i) any
inaccurate representation or any act or omission set forth in Section 2.02(a) above and (ii) any other factor or cause that independently or together with the factors or causes set forth in clause (i) above contributes to (or results
in) a liability for Transaction Taxes, then such liability for Transaction Taxes and Third Party Transaction Taxes shall be shared by the Parent Group and the Prothena Group according to relative fault. 

(d) The party liable for any Transaction Taxes shall be entitled to any Refund of such Transaction Taxes, and, if another party
subsequently receives (or realizes) any such Refund, such party shall, within 30 days, remit the amount of such Refund, net of any Taxes incurred by such party (or any member of its group) in connection with such Refund, to the party entitled to
such Refund under this Agreement. 
 Section 2.03 Transfer Taxes. 

(a) The Parent Group shall be liable for any Transfer Taxes, except to the extent that such liability would not have arisen but for a
voluntary transaction, action or omission carried out, effected or made by any Prothena Group member at any time after the Demerger. The parties shall cooperate in good faith to minimize the amount of any Transfer Taxes and obtain any Refunds
thereof. 
 (b) Without prejudice to the generality of Section 2.03(a) above, Parent shall indemnify Prothena against, and
hold it harmless from, any liability for any Irish stamp duty which Prothena is properly required to pay if it shall be determined that section 80 of the SDCA 

  
 -8-

 
did not apply to the transfer of the shares in Neotope Biosciences Limited pursuant to the Prothena Transfer, except to the extent that such liability would not have arisen but for a voluntary
transaction, action or omission carried out, effected or made by any Prothena Group member at any time after the Demerger. 

(c) In the case of any Transfer Taxes which have given rise to a claim by the Prothena Group under Section 2.03(a) or (b), if the
Prothena Group subsequently receives a Refund of any such Transfer Taxes, Prothena shall remit, within 30 days, to Parent the Refund received by the Prothena Group net of Taxes or other expenses incurred by the Prothena Group in connection with the
Refund. 
 Section 2.04 Entitlement to Tax Attributes. 

Prothena shall procure that each Prothena Group member shall make such surrenders of Irish Group Relief in respect of any accounting
period beginning on or before the Closing Date to any Parent Group member as Parent may, in its sole discretion, direct, provided always that Prothena shall be under no obligation to procure that the Prothena Group make any surrender of Irish Group
Relief to the extent that such surrender cannot lawfully be made. Prothena shall procure that each Prothena Group member, and Parent shall procure that each Parent Group member, shall use all reasonable endeavours to procure that full effect is
given to the surrenders to be made pursuant to this Section 2.04 and that such surrenders are allowed in full by the Irish Revenue Commissioners and (without prejudice to the generality of the foregoing) shall, at each party’s own cost,
sign and submit to the Irish Revenue Commissioners all such Tax returns and other documents as may be necessary to secure that full effect is given to this Section 2.04. For the avoidance of doubt, no payment shall be made by any Parent Group
member to any Prothena Group member in respect of any surrender made pursuant to this Section 2.04. 
 Section 2.05
Additional Costs. 
 Each Party shall be entitled to indemnification for Additional Costs related to any indemnity payment
under this Agreement. 
 ARTICLE III 
 TAX RETURN FILING AND PAYMENT OBLIGATIONS 
 Section 3.01 Tax Return
Preparation and Filing 
 (a) Subject to Section 3.03, Parent shall prepare and file, or shall cause to be prepared and
filed, all Joint Returns required to be filed under applicable Tax law after the date hereof (including any Joint Returns required to be filed for the taxable period in which the Transactions occur), and shall pay, or cause to be paid, all Taxes
shown to be due and payable on such Joint Returns; provided that Prothena shall (i) provide Parent, within 15 days of its request, with all information requested by Parent for purposes of calculating the Prothena Group’s items of
income, gain, loss, deduction or expense to be reported on any such Joint Return, and (ii) pay to Parent the Prothena Group’s share, if any, of any Tax liability reported on such Joint Return,

  
 -9-

 
within five days of Parent’s delivery of a reasonably detailed calculation of such Tax liability, which calculation shall be made by the Parent Group in accordance with its past practices.
Subject to Section 3.02, Prothena shall prepare and file, or shall cause to be prepared and filed, all Prothena Separate Returns required to be filed under applicable Tax law after the date hereof, and shall pay, or cause to be paid, all Taxes
shown to be due and payable on such Prothena Separate Returns. 
 (b) Except as required by any Transaction Document, Prothena
shall not cause or permit any Prothena Group member to take any action on the Closing Date other than in the ordinary course of business, including the sale of any assets, distribution of any dividend or making of any Tax election. 

Section 3.02 Treatment of Transactions and Reporting Obligations. 

The parties shall report the Transactions for all applicable Tax purposes in a manner consistent with the Tax Opinions, unless, and then
only to the extent, an alternative position is required pursuant to a Final Determination. Parent shall determine the Tax reporting of any issue relating to the Transactions that is not covered by the Tax Opinion. The parties shall comply (and cause
their subsidiaries to comply) with all applicable reporting requirements of U.S. Treasury Regulation Section 1.368-3. 

Section 3.03 VAT. 
 (a) Parent shall procure that, effective as of the Closing Date, Neotope Biosciences and Onclave shall cease to be members of a group within the meaning of section 15 of the VATCA in respect of which any
Parent Group member is also a member (a “VAT Group”). 
 (b) Prothena shall procure that Neotope Biosciences or
Onclave, as appropriate, pay to Parent (or to such Parent Group member as Parent may direct) the appropriate Prothena Group member’s share, if any, of any VAT liability for which any Parent Group member is liable in respect of the VAT due on
supplies by Neotope Biosciences or Onclave for a Straddle Period, and such payment shall be made within 5 days of Parent’s delivery of a reasonably detailed calculation of such VAT liability, which calculation shall be made by the Parent Group
in accordance with its past practices. Parent shall prepare and file, or shall cause to be prepared and filed, any Tax return required to be filed under applicable Tax law by any VAT Group in respect of a Straddle Period, and shall pay, or cause to
be paid, all Taxes shown to be due and payable on such Tax return. 
 ARTICLE IV 

TAX-FREE TREATMENT OF DISTRIBUTION & RELATED TRANSACTIONS 

Section 4.01 Representations. 
 (a) Parent represents and warrants that, as of the Closing Date, (i) the Transaction Documents, including all statements in the Transaction Documents by or about the

  
 -10-

 
Prothena Group, are true, correct and complete in all material respects, and Parent knows of no other facts that could cause any Transaction to fail to qualify for Tax-Free Treatment, and
(ii) it has no plan or intention to take any action inconsistent with the Parent Representation Letter or any covenant of any Parent Group member set forth in any Transaction Document. 

(b) Prothena represents and warrants that, as of the Closing Date, (i) all statements in the Transaction Documents by or about the
Prothena Group, and any member thereof, are true, correct and complete in all material respects, and Prothena knows of no other facts that could cause any Transaction to fail to qualify for Tax-Free Treatment, and (ii) it has no plan or
intention to take any action inconsistent with the Prothena Representation Letter or any covenant of any Prothena Group member set forth in any Transaction Document. 
 Section 4.02 Covenants. 
 (a) During the Restricted Period,
(i) neither Parent nor any of its Affiliates (or any officers or directors acting on behalf of Parent or any of its subsidiaries, or any Person acting with the implicit or explicit permission of any such officers or directors) shall take or
fail to take any action if such action (or the failure to take such action) would (x) be inconsistent with any covenant, representation or statement made by, Parent or any of its Affiliates in the Parent Representation Letter or in any
Transaction Document, or (y) prevent, or be reasonably likely to prevent, the Transactions (or any portion thereof) from qualifying for Tax-Free Treatment; and (ii) none of Prothena or any of its Affiliates (or any officers or directors
acting on behalf of Prothena or any of its subsidiaries, or any Person acting with the implicit or explicit permission of any such officers or directors) shall take or fail to take any action if such action (or the failure to take such action) would
(x) be inconsistent with any covenant, representation or statement made by, Prothena or any of its Affiliates in the Prothena Representation Letter or in any Transaction Document, or (y) prevent, or be reasonably likely to prevent, the
Transactions (or any portion thereof) from qualifying for Tax-Free Treatment. 
 (b) Without limiting the generality of the
foregoing, during the Restricted Period and subject to Section 4.02(d), neither Prothena nor any of its Affiliates (or any officers or directors acting on behalf of Prothena or any of its subsidiaries, or any Person acting with the implicit or
explicit permission of any such officers or directors) shall: 
 (i) merge or consolidate Prothena with any other
Person, or liquidate or partially liquidate Prothena; 
 (ii) cause or permit Prothena to be treated as other
than a corporation for U.S. federal income Tax purposes; 
 (iii) discontinue, sell, transfer or cease to
maintain the Active Trade or Business (including by failing to make reasonable efforts to pursue opportunities to perform research and development services for unrelated parties with whom Prothena or any of its subsidiaries is otherwise
collaborating), or engage in any transaction that could result in Prothena ceasing to be engaged in the Active Trade or Business; 
 (iv) redeem, repurchase or otherwise acquire any outstanding Prothena Capital Stock; 

  
 -11-

 (v) issue any shares of Prothena Capital Stock, other than shares of
Prothena Capital Stock issued in the Equity Investment and to employees of the Prothena Group as compensation for services; 
 (vi) amend, terminate or fail to enforce the terms of any proxy agreement entered into between Parent and Prothena with respect to the voting of Parent’s shares of Prothena Capital Stock; 

(vii) take any action that permits a proposed acquisition of Prothena Capital Stock to occur by means of an agreement to
which Prothena is a party, including by (x) soliciting any Person to make a tender offer for, or otherwise acquire or sell, Prothena Capital Stock (other than the Equity Investment and shares of Prothena Capital Stock issued to employees of the
Prothena Group as compensation for services) or approving or otherwise permitting any such transaction, (y) participating in or otherwise supporting any unsolicited tender offer for, or other unsolicited acquisition or disposition of, Prothena
Capital Stock or approving or otherwise permitting any such transaction, or (z) making a determination that a tender offer is a “permitted offer” under any such plan or otherwise causing any such plan to be inapplicable or neutralized
with respect to any proposed acquisition of Prothena Capital Stock; or 
 (viii) without duplication for
Section 4.02(b)(iii), sell, transfer or otherwise cease to be the beneficial owner of the shares of Neotope Biosciences acquired by Prothena pursuant to the Prothena Transfer. 

(c) To the extent that, as a result of a subsequent amendment to the Code and/or the U.S. Treasury Regulations, any action or a failure
to take any action by a Parent Group member or a Prothena Group member could affect any Transaction’s qualification for Tax-Free Treatment, then the covenants contained in Section 4.02(a)(i)(y) and in Section 4.02(a)(ii)(y) shall
automatically be deemed to incorporate by reference such actions and the failure to take such actions, and the Prothena Group shall comply with the requirements of the relevant amendment through the end of the Restricted Period; provided,
however, that, for the avoidance of doubt, no such action or failure to take any such action before the date the relevant amendment is enacted shall constitute a breach of such Sections to the extent such actions or failure to take such
actions would not have otherwise constituted a breach of such Sections before such date. 
 (d) For the avoidance of doubt,
neither the Prothena Group nor any of its Affiliates shall take any action prohibited by Section 4.02(b) or Section 4.02(c), unless (i) Parent receives prior written notice describing the proposed action in reasonable detail, and
(ii) the Prothena Group delivers to Parent an Unqualified Opinion and Parent, in its reasonable discretion, which discretion shall be exercised in good faith solely to preserve the Tax-Free Treatment, provides its written consent permitting the
proposed action. Parent’s obligation to cooperate in connection with the Prothena Group’s delivery of an Unqualified Opinion is as expressly set forth in Section 5.06(b) below. For the avoidance of doubt, the Parent Group’s right
to indemnification for Transaction Taxes shall be determined without regard to whether the Prothena Group satisfies any or all of the requirements of this Section 4.02(d). 

  
 -12-

 (e) After the Distribution, each of Prothena and its Affiliates shall maintain its books and
records for financial reporting and, to the extent applicable, U.S. federal income Tax purposes using the accrual method of accounting. 
 ARTICLE V 
 TAX CONTESTS; INDEMNIFICATION; COOPERATION 

Section 5.01 Notice. 
 Within 30 days after a party (the “Indemnitee”) becomes aware of the existence of a Tax Contest that may give rise to an indemnification claim by it against another party under this
Agreement (each such party, an “Indemnifying Party”), the Indemnitee shall promptly notify the Indemnifying Parties of the Tax Contest, and thereafter shall promptly forward or make available to the Indemnifying Parties copies of
all notices and communications with a Taxing Authority solely to the extent relating to such Tax Contest; provided, however, that any delay on the part of the Indemnitee in notifying the Indemnifying Parties shall not relieve the Indemnifying
Parties from any obligation hereunder unless (and then solely to the extent) the Indemnifying Parties are actually prejudiced thereby. 
 Section 5.02 Control of Tax Contests. 
 Parent shall have the right to
(i) contest, compromise or settle any adjustment or deficiency proposed or asserted with respect to any Tax liability with respect to a Joint Return or any Irish stamp duty liability which Prothena is required to pay if it shall be asserted
that section 80 of the SDCA did not apply to the transfer of the shares in Neotope Biosciences pursuant to the Prothena Transfer, and (ii) file, prosecute, compromise or settle any Adjustment Request (and determine the manner in which any
Refund shall be received) with respect to any Tax addressed in clause (i) immediately above; provided that, to the extent a Tax Contest solely relates to Transaction Taxes with respect to which the Prothena Group could be liable under
Section 2.02(a), Parent shall reasonably consult with the Prothena Group with respect to Parent’s defense and control of such Tax Contest. 
 Section 5.03 Indemnification Payments. 
 An Indemnitee shall be
entitled to make a claim, including, for the avoidance of doubt, any claim for Third Party Transaction Taxes, for payment pursuant to this Agreement at the time the Indemnitee determines that it is entitled to such payment. The Indemnitee shall
provide to the Indemnifying Parties notice of such claim within 30 days of the date on which it first determines that it is entitled to claim such payment, including a description of such claim and a detailed calculation of the amount of the
indemnification payment that is claimed; provided, however, that any delay on the part of the Indemnitee in notifying the Indemnifying Parties shall not relieve the Indemnifying Parties from any obligation hereunder unless (and then solely to the
extent) the Indemnifying Parties are actually prejudiced thereby. Unless the Indemnifying Parties reasonably dispute their liability for, or the amount of, an indemnity payment, such parties shall make the claimed payment to the Indemnitee within 10
days after receiving notice of (i) the Indemnitee’s payment of a Tax for which the Indemnifying Parties are liable under this Agreement, or (ii) a Final Determination which results in the Indemnifying Parties becoming obligated to
make a payment to the Indemnitee under this Agreement. 

  
 -13-

 Section 5.04 Interest on Late Payments. 

With respect to any indemnification payment (including any disputed payment that is ultimately required to be paid) not made by the due
date for payment set forth in this Agreement, interest shall accrue at a rate of 2% above EURIBOR for the period from the date falling 30 Business Days after the due date to the date of actual payment. 

Section 5.05 Treatment of Indemnity Payments. 
 Except for any payment of interest under Section 5.04 and in the absence of a Final Determination to the contrary, any amount payable with respect to any Tax under this Agreement shall, to the extent
permitted under applicable Tax law, be treated as occurring immediately prior to the Transactions, as an inter-company distribution or a contribution to capital, as the case may be. Notwithstanding the foregoing, the amount of any indemnity payment
under this Agreement shall be (i) decreased to take into account any Tax benefit actually realized by the Indemnitee (or an Affiliate thereof) arising from the incurrence or payment of the relevant indemnified item, and (ii) increased to
take into account any Tax cost actually incurred by the Indemnitee (or an Affiliate thereof) arising from the receipt of the relevant indemnity payment. Any indemnity payment will initially be made without regard to this Section 5.05 and will
be reduced or increased to reflect any applicable Tax benefit or Tax cost, as the case may be, within 30 days after the Indemnitee (or an Affiliate thereof) actually realizes such Tax benefit or incurs such Tax cost by way of a Refund, an increase
in Taxes or otherwise. In the event of a Final Determination relating to the Indemnitee’s (or its Affiliate’s) incurrence or payment of an indemnified item and/or receipt of an indemnity payment pursuant to this Section 5.05, the
Indemnitee will, within 30 days of such Final Determination, provide the other parties with notice thereof and supporting documentation addressing, in reasonable detail, the amount of any reduction or increase in Taxes of the Indemnitee (or its
Affiliate) resulting from such Final Determination, and the parties will promptly make any payments necessary to reflect the relevant reduction or increase in Tax liability. 
 Section 5.06 Cooperation. 
 (a) Pursuant to this Agreement, each member
of the Parent Group and the Prothena Group shall cooperate fully with all reasonable requests from the other parties in connection with the preparation and filing of Tax Returns and Adjustment Requests, the resolution of Tax Contests and any other
matters covered herein. If any parties fail to comply with any of their obligations set forth in this Section 5.06(a), and such failure results in the imposition of additional Taxes, the nonperforming parties shall be liable for such additional
Taxes. 
 (b) In connection with the foregoing, Parent shall, at Prothena’s sole expense, reasonably cooperate with
Prothena, upon its written request, in connection with obtaining an Unqualified Opinion; provided, however, that Parent’s cooperation shall not affect the Parent Group’s indemnity obligation for Taxes under this Agreement,
decrease in any respect the Prothena Group’s indemnity obligation for Taxes under this Agreement, or cause any member of the Parent Group to have any liability to any third party. 

  
 -14-

 Section 5.07 Confidentiality. 

Any information or document provided under this Agreement shall be kept confidential by the recipient parties, except as may otherwise be
necessary in connection with the filing of any Tax Return or the resolution of any Tax Contest. In addition, if Parent or Prothena determines that providing any information or document could be commercially detrimental, violate any law or agreement
or waive any privilege, the parties shall use their reasonable best efforts to permit compliance with the obligations under this Agreement in a manner that avoids any such harm or consequence. 

ARTICLE VI 

DISPUTE RESOLUTION 
 Section 6.01 Tax Disputes. 
 The parties shall endeavor, and shall
cause their respective Affiliates to endeavor, to resolve in good faith all disputes arising in connection with this Agreement. The parties shall negotiate in good faith to resolve any Tax Dispute within 30 days. Upon written notice by a party after
such 30-day period, the matter will be referred to a U.S. tax counsel or other tax advisor of recognized national standing (the “Tax Advisor”) that will be jointly chosen by Parent and Prothena; provided, however, that, if Parent
and Prothena do not agree on the selection of the Tax Advisor after 10 days of good faith negotiation, their respective U.S. or Irish tax counsel or other advisors of recognized national standing shall select a mutually acceptable Tax Advisor within
the following 10-day period. The Tax Advisor may, in its discretion, obtain the services of any third party necessary to assist the Tax Advisor in resolving the Tax Dispute. The Tax Advisor shall furnish written notice to the Companies of its
resolution of the Tax Dispute as soon as practicable, but in any event no later than 90 days after acceptance of the matter for resolution. Any such resolution by the Tax Advisor shall be binding on the parties, and the parties shall take, or cause
to be taken, any action necessary to implement such resolution. All fees and expenses of the Tax Advisor shall be shared equally by Parent and the Prothena Group. If the parties are unable to find a Tax Advisor willing to adjudicate the Tax Dispute
and whom the parties, acting in good faith, find acceptable (under the standards set forth in this Section 6.01), (i) the Tax Dispute will be submitted for mediation, and (ii) if the Tax Dispute is not resolved in mediation, either
party will have the right to commence litigation, in a manner consistent with Clause 30 of the Demerger Agreement. If any dispute regarding the preparation of a Tax Return is not resolved before the due date for filing such return, the return shall
be filed in the manner deemed correct by the party responsible for filing the return without prejudice to the rights and obligations of the parties hereunder; provided that the preparing party shall file an amended Tax Return, within 10 days after
the completion of the process set forth in this Section 6.01, reflecting any changes made in connection with such process. 

  
 -15-

 ARTICLE VII 
 MISCELLANEOUS 
 Section 7.01 Authorization. 

Each party hereby represents and warrants that it has the power and authority to execute, deliver and perform this Agreement, that this
Agreement has been duly authorized by all necessary corporate action on the part of such party, that this Agreement constitutes a legal, valid and binding obligation of such party, and that the execution, delivery and performance of this Agreement
by such party does not contravene or conflict with any provision of law or of its charter or bylaws or any agreement, instrument or order binding on such party. 
 Section 7.02 Expenses. 
 Except as otherwise provided in this Agreement
or any other Transaction Document, each party will bear its own expenses in connection with the matters addressed herein. 

Section 7.03 Entire Agreement. 
 This Agreement and the other Transaction Documents, including any related annexes, schedules and exhibits, as well as any other agreements and documents referred to herein and therein, will together
constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and will supersede all prior negotiations, agreements and understandings of the parties of any nature, whether oral or written, with respect to
such subject matter. 
 Section 7.04 Governing Law. 

This Agreement is governed by and shall be construed in accordance with the laws of Ireland. The courts of Ireland are to have exclusive
jurisdiction to settle any dispute, whether contractual or non-contractual, arising out of or in connection with this Agreement. Any proceeding, suit or action arising out of or in connection with this Agreement or the negotiation, existence,
validity or enforceability of this Agreement (“Proceedings”) shall be brought only in the courts of Ireland. Each of the Companies waives (and agrees not to raise) any objection, on the ground of forum non conveniens or on
any other ground, to the taking of Proceedings in the courts of Ireland. Each Party also agrees that a judgment against such party in Proceedings brought in shall be conclusive and binding upon such party and may be enforced in any other
jurisdiction. Each of the Companies irrevocably submits and agrees to submit to the jurisdiction of the courts of Ireland. 

Section 7.05 Notice. 
 All notices, requests, permissions, waivers and other communications hereunder will be in writing and will be deemed to have been duly given (i) five Business Days following sending by registered or
certified mail, postage prepaid, (ii) when sent, if sent by facsimile; provided that the facsimile transmission is promptly confirmed by telephone, (iii) when 

  
 -16-

 
delivered, if delivered personally to the intended recipient, and (iv) one Business Day following sending by overnight delivery via a national courier service and, in each case, addressed to
a party at the following address for such party: 
  

			
	If to Parent:                    	  	 Elan Corporation, plc
 Treasury
Building
 Lower Grand Canal Street

Dublin 2
 Ireland

Tel.: +353 1 709 4000
 Fax: +353 1 709
4713
 Attention: William F. Daniel, Company Secretary
  

with a copy to (which shall not constitute notice):
  

A&L Goodbody
 International Financial
Services Centre
 North Wall Quay

Dublin 1
 Tel.: +353 1 649 2000

Fax: +353 1 649 2649
 Attention: John
Given/Darragh O’Dea
  
 and

 
 Cadwalader, Wickersham & Taft LLP

One World Financial Center
 New York, NY
10281
 USA
 Tel.: +1 212 504
6000
 Fax: + 212 504 6666
 Attention:
Christopher T. Cox

		
	If to Prothena:	  	 Prothena Corporation plc
 650
Gateway Boulevard
 South San Francisco

CA 94080
 U.S.A.

Tel.: +1 650-837-8550
 Fax: + 2
650-837-8560
 Attention: Dale Schenk, CEO

  
 -17-

			
		  	 with a copy to (which shall not constitute notice):
  

Prothena Corporation plc
 25-28 North Wall
Quay
 Dublin 1
 Ireland

Tel.: +353 1 649 2000
 Fax: +353 1 649
2649
 Attention: John Given

 or to such other address(es) as will be furnished in writing by any such party to the other party in accordance with the
provisions of this Section 7.05. Any notice to Parent will be deemed notice to all members of the Parent Group and any notice to Prothena will be deemed notice to all members of the Prothena Group. 

Section 7.06 Priority of Agreements. 
 If there is a conflict between any provision of this Agreement and a provision in another Transaction Document, the provision of this Agreement will control, unless specifically provided otherwise in this
Agreement or in the applicable Transaction Document. 
 Section 7.07 Amendments and Waivers. 

(a) This Agreement may be amended and any provision of this Agreement may be waived; provided that any such amendment or waiver
will be binding upon a party only if such amendment or waiver is set forth in a writing executed by such party. No course of dealing between or among any Persons having any interest in this Agreement will be deemed effective to modify, amend or
discharge any part of this Agreement or any rights or obligations of any party hereto under or by reason of this Agreement. 

(b) No delay or failure in exercising any right, power or remedy hereunder will affect or operate as a waiver thereof; nor will any
single or partial exercise thereof or any abandonment or discontinuance of steps to enforce such a right, power or remedy preclude any further exercise thereof or of any other right, power or remedy. The rights and remedies hereunder are cumulative
and not exclusive of any rights or remedies that any party hereto would otherwise have. Any waiver, permit, consent or approval of any kind or character of any breach or default under this Agreement or any such waiver of any provision of this
Agreement must satisfy the conditions set forth in this Section 7.07(b) and will be effective only to the extent in such writing specifically set forth. 
 Section 7.08 Termination. 
 This Agreement shall automatically
terminate, without further action by any party hereto, upon the termination of the Demerger Agreement if such termination occurs prior to the Distribution. If terminated, no party will have any liability of any kind to the other parties or any other
Person on account of the termination or otherwise with respect to this Agreement. 

  
 -18-

 Section 7.09 No Third Party Beneficiaries. 

Except as otherwise provided in the indemnification provisions contained herein, this Agreement is solely for the benefit of the parties
hereto and does not confer on third parties (including any employees of any member of the Parent Group or the Prothena Group) any remedy, claim, reimbursement, claim of action or other right in addition to those existing without reference to this
Agreement. 
 Section 7.10 Assignability. 
 No party will assign its rights or delegate its duties under this Agreement without the written consent of the other parties, except that any party may assign its rights or delegate its duties under this
Agreement to an Affiliate; provided that such assigning party agrees in writing to be bound by the terms and conditions contained in this Agreement, and provided, further, that the assignment or delegation will not relieve any party of its
indemnification obligations or obligations in the event of a breach of this Agreement. Except as provided in the preceding sentence, any attempted assignment or delegation will be void. 

Section 7.11 Enforcement. 
 The parties agree that irreparable damage would occur to Parent and Prothena in the event that any provision of this Agreement were not performed in accordance with the terms hereof. The parties agree
that Parent and Prothena shall be entitled to injunctive relief to prevent any breach of this Agreement and to enforce specifically the terms and provisions hereof, such remedy being in addition to any other remedy to which a party may be entitled
at law or in equity. 
 Section 7.12 Survival. 

All Sections of this Agreement shall be unconditional and absolute and shall remain in effect without limitation as to time (except to the
extent any Sections expressly provide for an earlier date, in which case, as of such date). 
 Section 7.13
Construction. 
 The descriptive headings herein are inserted for convenience of reference only and are not intended to be
a substantive part of or to affect the meaning or interpretation of this Agreement. Reference to any agreement, document, or instrument means such agreement, document, or instrument as amended or otherwise modified from time to time in accordance
with the terms thereof, and if applicable hereof. The use of the words “include” or “including” in this Agreement will be by way of example rather than by limitation. The use of the words “or,” “either” or
“any” will not be exclusive. The parties have participated jointly in the negotiation and drafting of this Agreement, and the parties acknowledge that, in the event an ambiguity or question of intent or interpretation arises, this
Agreement will be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof will arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Except as otherwise
expressly provided elsewhere in this Agreement or any other Transaction Document, any provision herein which contemplates the agreement, approval or consent of, or exercise of any right of, a party, such party may give or withhold such agreement,
approval or consent, or exercise such right, in its sole and absolute discretion, the parties hereto hereby expressly disclaiming any implied duty of good faith and fair dealing or similar concept. 

  
 -19-

 Section 7.14 Severability. 

The parties agree that (i) the provisions of this Agreement shall be severable in the event that for any reason whatsoever any of the
provisions hereof are invalid, void or otherwise unenforceable, (ii) any such invalid, void or otherwise unenforceable provisions shall be replaced by other provisions which are as similar as possible in terms to such invalid, void or otherwise
unenforceable provisions but are valid and enforceable, and (iii) the remaining provisions shall remain valid and enforceable to the fullest extent permitted by Applicable Law. 

Section 7.15 Counterparts. 
 This Agreement may be executed in multiple counterparts (any one of which need not contain the signatures of more than one party), each of which will be deemed to be an original but all of which taken
together will constitute one and the same agreement. This Agreement, and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or other electronic transmission, will be treated in all manner and respects as an
original agreement and will be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. At the request of any party, the other parties will re-execute original forms thereof and deliver
them to the requesting party. No party will raise the use of a facsimile machine or other electronic means to deliver a signature or the fact that any signature was transmitted or communicated through the use of facsimile machine or other electronic
means as a defense to the formation of a Contract and each such party forever waives any such defense. 
 Section 7.16
Successors. 
 For the avoidance of doubt, for all purposes of this Agreement, a party shall be subject to all of the
restrictions and obligations, and shall have all of the rights, of such party’s predecessor. 
 -- 

  
 -20-

 IN WITNESS whereof this Agreement has been duly executed as a deed by the parties to it on
the date set out at the beginning of this Agreement. 
  

							
	 GIVEN UNDER THE COMMON SEAL
 of ELAN CORPORATION, PLC
 in the presence of:
	 		 	
				
		 		 		 	/s/ Nigel Clerkin
		 		 		 	Signature of Authorised Signatory
		 		 		 	
				
		 		 		 	/s/ William F. Daniel
		 		 		 	Signature of Director/Secretary
			
	 GIVEN UNDER THE COMMON SEAL
 of PROTHENA CORPORATION PLC
 in the presence of:
	 		 	
				
		 		 		 	/s/ Nigel Clerkin
		 		 		 	Signature of Director
		 		 		 	
				
		 		 		 	/s/ William F. Daniel
		 		 		 	Signature of Director/Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]